ACTA1 and chronic kidney disease: Clinically, a randomized controlled trial showed that treatment with Qingshen granules could lower the levels of serum Wnt1, β-catenin, α-SMA, and E-cadherin in patients with chronic renal failure (Wang et al., 2019).